Ligand Pharmaceuticals Incorpor
Ligand Pharmaceuticals develops and licenses biopharmaceutical assets worldwide. Commercial programs include Kyprolis, Evomela, Rylaze, Filspari, Teriparatide, Vaxneuvance, Pneumosil, and others. Products also include TZIELD, Nexterone, Zulresso, Veklury, Noxafil-IV, Duavee, Exemptia, Vivitra, Bryxta, and Zybev. The company has alliances with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Ligand also sells Captisol materials.
Overview
Strengths
- High-quality earnings: over the last 6 years, free cash flow added up to 182% of reported net income.
Weaknesses
- Our discounted cash flow target price (23.55 USD) is 92% below the current price.
- Unstable profitability: operating margin ranged from 2% to 43% over the last 6 years.
- Valued at a premium to its Biotechnology peers: P/E 47.5x vs. a median of 19.2x and EV/EBITDA 65.5x vs. a median of 15.0x.
- Shareholder dilution: the share count has grown by 5.3% a year over the last three years.
- Earnings are projected to decline (-10.0% per year).
- More expensive than its own history: EV/EBITDA 65.5x vs. a historical average of 24.7x.
Key Financial Data